title: The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase.
abstract: The endogenous cannabinoid receptor ligand, anandamide (AEA), is a full agonist of the vanilloid receptor type 1 (VR1) for capsaicin. Here, we demonstrate that the potency and efficacy of AEA at VR1 receptors can be significantly increased by the concomitant activation of protein kinase A (PKA). In human embryonic kidney (HEK) cells over-expressing human VR1, AEA induces a rise in cytosolic Ca(2+) concentration that is mediated by this receptor. The EC(50) for this effect was decreased five-fold in the presence of forskolin (FRSK, 1-5 microM) or the cAMP analogue, 8-Br-cAMP (10-100 microM). The effects of 8-Br-cAMP and FRSK were blocked by a selective PKA inhibitor. The FRSK (10 nM) also potently enhanced the sensory neurone- and VR1-mediated constriction by AEA of isolated guinea-pig bronchi, and this effect was abolished by a PKA inhibitor. In rat dorsal root ganglia slices, AEA-induced release of substance P, an effect mediated by VR1 activation, was enhanced three-fold by FRSK (10 nM). Thus, the ability of AEA to stimulate sensory VR1, with subsequent neuropeptide release, appears to be regulated by the state of activation of PKA. This observation supports the hypothesis that endogenous AEA might stimulate VR1 under certain pathophysiological conditions.
authors: Endocannabinoid Research Group, Istituto di Cibernetica (LDP), Consiglio Nazionale delle Ricerche, Arco Felice, Italy.
authors: L
authors: L
authors: De Petrocellis
authors: S
authors: S
authors: Harrison
authors: T
authors: T
authors: Bisogno
authors: M
authors: M
authors: Tognetto
authors: I
authors: I
authors: Brandi
authors: G D
authors: GD
authors: Smith
authors: C
authors: C
authors: Creminon
authors: J B
authors: JB
authors: Davis
authors: P
authors: P
authors: Geppetti
authors: V
authors: V
authors: Di Marzo
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects / Q000502:physiology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002460:Cell Line; D005576:Colforsin / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D063388:Endocannabinoids; D006168:Guinea Pigs; D006801:Humans; D007668:Kidney / Q000166:cytology; D008297:Male; D053284:Polyunsaturated Alkamides; D051381:Rats; D017207:Rats, Sprague-Dawley; D011955:Receptors, Drug / Q000378:metabolism*; D013373:Substance P / Q000494:pharmacology
chemical_list: D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D011955:Receptors, Drug; D005576:Colforsin; D015124:8-Bromo Cyclic Adenosine Monophosphate; D013373:Substance P; D017868:Cyclic AMP-Dependent Protein Kinases; D002118:Calcium; C078814:anandamide